SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

LRMR

Larimar Therapeutics Inc.
NASDAQHealth Care

Latest close: 1.99 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 29, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Aug 4, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
  3. Aug 4, 2026Material event · 8-KFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record65016 flagged findings
Reported transactions (Form 4)75since Jan 31, 2023
Corporate events (8-K)30since Dec 18, 2019

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 650)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Oct 1, 26Form 4 ↗Insider transaction
  • Oct 1, 26Form 3 ↗Insider transaction
  • Sep 29, 268-K ↗Current report · A senior executive left or was appointed
  • Aug 4, 2610-Q ↗Quarterly report
  • Aug 4, 268-K ↗Current report · Results · Other events
  • Jul 8, 26Form 4 ↗Insider transaction
  • Jun 29, 268-K ↗Current report · Other events
  • Insider transaction · 6 Form 4 filingsshow all 6hide
  • May 19, 268-K ↗Current report · Shareholder vote results
  • May 14, 2610-Q ↗Quarterly report
  • May 14, 268-K ↗Current report · Results · Other events
  • May 14, 26SCHEDULE 13G/A ↗Passive stake · Blue Owl Capital Holdings LP · 10.0% · event on Mar 31, 26 · amendment
  • Apr 30, 26SCHEDULE 13G/A ↗Passive stake · Millennium Management LLC · 3.5% · event on Mar 31, 26 · amendment
  • Apr 20, 26DEF 14A ↗Shareholder meeting and votes
  • Apr 10, 26PRE 14A ↗Shareholder meeting and votes
  • Mar 19, 2610-K ↗Annual report
  • Mar 19, 268-K ↗Current report · Results
  • Mar 9, 268-K ↗Current report · Other events
  • Mar 2, 26SCHEDULE 13D/A ↗Stake with intent to influence · Deerfield Management Company, L.P. · 34.4% · event on Feb 27, 26 · amendment
  • Mar 2, 26Form 4 ↗Insider transaction

650 filings on record, the oldest from Feb 28, 14.

Listing the 25 most recent filings of the 650 on record.

8-Ks, explained

Stress3Structure24Governance24
  • Sep 29, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Feb 27, 26StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Jan 22, 26StructureSold unregistered shares+2 more in the same filing8-K 3.02 ↗
  • Dec 17, 25StructureSold unregistered shares+2 more in the same filing8-K 3.02 ↗
  • Jul 31, 25StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Jan 27, 25GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Feb 16, 24StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Feb 14, 24StructureA material agreement was terminated8-K 1.02 ↗
  • Oct 3, 23GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Apr 6, 23GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Sep 14, 22StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • May 12, 22GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗

11 older filings not shown · The record reaches back to Jun 24, 14.

Notable in the record

Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.

  • Apr 24, 20StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Sep 19, 19StressListing notice (8-K 3.01)8-K 3.01 ↗
  • Sep 12, 19StressRestructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗

The full record holds 3 stress filings.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • Deerfield Management Company, L.P.34.4%Feb 27, 26SCHEDULE 13D/A ↗10 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • JANUS HENDERSON GROUP PLC10.1%Dec 31, 24SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
  • Blue Owl Capital Holdings LP10.0%Mar 31, 26SCHEDULE 13G/A ↗1 earlier filing
  • Janus Henderson Biotech Innovation Master Fund Ltd9.1%Mar 31, 25SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
  • Opaleye Management, Inc.4.8%Aug 29, 25SCHEDULE 13G ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • BlackRock, Inc.4.8%Mar 31, 25SCHEDULE 13G/A ↗1 earlier filing
show 2 more holdershide
  • THE GOLDMAN SACHS GROUP, INC.4.1%Mar 31, 25SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
  • Millennium Management LLC3.5%Mar 31, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Jul 6, 26Buy$167KThomas Edward Hamilton↗
  • Feb 27, 26Buy$25KJEFFREY W SHERMAN↗
  • Feb 27, 26Buy$25KFRANK E THOMAS↗
  • Feb 27, 26Buy$500KThomas Edward Hamilton↗
  • Feb 27, 26Buy$5.4MJames E Flynn↗
  • Feb 27, 26Buy$5.4MJames E Flynn↗
  • Feb 27, 26Buy$4.2MJames E Flynn↗
  • Feb 27, 26Buy$10.0MJames E Flynn↗
  • Jul 31, 25Buy$10.8MJames E Flynn↗
  • Jul 31, 25Buy$10.8MJames E Flynn↗
  • Jul 31, 25Buy$8.3MJames E Flynn↗
  • Feb 16, 24Buy$500KThomas Edward Hamilton↗

There are 8 more transactions in this stretch.

Stock compensation, tax and giftsshow the 15 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Sep 29, 26Compensationamount n/aJohn B. Harlow Jr.President and COO↗
  • Jan 26, 26Compensationamount n/aMichael CelanoChief Financial Officer↗
  • Jan 26, 26Compensationamount n/aCAROLE BEN-MAIMONPresident and CEO↗
  • Jan 26, 26Compensationamount n/aRussell ClaytonChief Medical Officer↗
  • Jan 26, 26Compensationamount n/aGopi ShankarChief Development Officer↗
  • Jan 22, 25Compensationamount n/aMichael CelanoChief Financial Officer↗
  • Jan 22, 25Compensationamount n/aCAROLE BEN-MAIMONPresident and CEO↗
  • Jan 22, 25Compensationamount n/aRussell ClaytonChief Medical Officer↗
  • Jan 22, 25Compensationamount n/aGopi ShankarChief Development Officer↗
  • Jan 17, 24Compensationamount n/aCAROLE BEN-MAIMONPresident and CEO↗
  • Jan 17, 24Compensationamount n/aRussell ClaytonChief Medical Officer↗
  • Jan 17, 24Compensationamount n/aMichael CelanoChief Financial Officer↗
  • Jan 17, 24Compensationamount n/aGopi ShankarChief Development Officer↗
  • Jan 31, 23Compensationamount n/aCAROLE BEN-MAIMONPresident and CEO↗
  • Jan 31, 23Compensationamount n/aMichael CelanoChief Financial Officer↗

The full record holds 35 transactions and goes back to Jan 31, 23.

Its sector and its market

Larimar Therapeutics Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Larimar Therapeutics Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Larimar Therapeutics Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
Series with incidents in the period; the chart shows what could be kept.
SEC records
650 documents on file, from Feb 28, 2014 to Oct 1, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.

Larimar Therapeutics Inc. (LRMR): stock price history, insider trades and SEC filings — HornScout